Showing 1 to 2 of 2 results


Sanofi to Acquire Vicebio for $1.6 Billion, Expanding Vaccine Portfolio
French pharmaceutical giant Sanofi is acquiring British biotech firm Vicebio for up to $1.6 billion, gaining access to its novel combination vaccine candidate for RSV and hMPV, and its 'Molecular Clamp' technology, with the deal expected to close in the fourth quarter of 2025.
Sanofi to Acquire Vicebio for $1.6 Billion, Expanding Vaccine Portfolio
French pharmaceutical giant Sanofi is acquiring British biotech firm Vicebio for up to $1.6 billion, gaining access to its novel combination vaccine candidate for RSV and hMPV, and its 'Molecular Clamp' technology, with the deal expected to close in the fourth quarter of 2025.
Progress
32% Bias Score

Sanofi Acquires Vicebio for €980 Million, Expanding Respiratory Vaccine Portfolio
Sanofi is acquiring British biotech firm Vicebio for €980 million plus potential milestone payments, gaining access to a combined hMPV/RSV vaccine and Molecular Clamp technology to accelerate vaccine development and address global respiratory infections.

Sanofi Acquires Vicebio for €980 Million, Expanding Respiratory Vaccine Portfolio
Sanofi is acquiring British biotech firm Vicebio for €980 million plus potential milestone payments, gaining access to a combined hMPV/RSV vaccine and Molecular Clamp technology to accelerate vaccine development and address global respiratory infections.
Progress
44% Bias Score
Showing 1 to 2 of 2 results